Of course, the responding group had more significant serum total IgE, EOS counts and percentages, and FEV1, which could explain more fully the evaluation of the efficacy of omalizumab in allergic asthma (Table 4, Figure 1). This evidence concerns the gene IGHE and allergic asthma.